Review article: genetic factors that modify the outcome of viral hepatitis (Q38198089)

30 August 2017

2 references

25 October 2022

Review article: genetic factors that modify the outcome of viral hepatitis (English)

1 reference

30 August 2017

1 reference

A F Stättermayer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24654629%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

T Scherzer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24654629%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

S Beinhardt

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24654629%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

K Rutter

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24654629%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

H Hofer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24654629%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

P Ferenci

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24654629%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

English

0 references

publication date

24 March 2014

1 reference

24654629

Alimentary Pharmacology & Therapeutics

30 August 2017

1 May 2014

1 reference

25 October 2022

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24654629%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

25 October 2022

39

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24654629%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24654629%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

1059-1070

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24654629%20AND%20SRC:MED&resulttype=core&format=json

A HapMap harvest of insights into the genetics of common disease

11 June 2020

cites work

1 reference

Genomic medicine--an updated primer

21 January 2018

1 reference

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

21 January 2018

1 reference

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

21 January 2018

1 reference

Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes

21 January 2018

1 reference

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice

21 January 2018

1 reference

Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection

21 January 2018

1 reference

Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts

21 January 2018

1 reference

Synergism of tapasin and human leukocyte antigens in resolving hepatitis C virus infection

21 January 2018

1 reference

IL-28, IL-29 and their class II cytokine receptor IL-28R

21 January 2018

1 reference

Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo

21 January 2018

1 reference

IFN-lambda: novel antiviral cytokines

21 January 2018

1 reference

Viral Infections Activate Types I and III Interferon Genes through a Common Mechanism

21 January 2018

1 reference

IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex

21 January 2018

1 reference

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

21 January 2018

1 reference

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

21 January 2018

1 reference

IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.

21 January 2018

1 reference

A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus

21 January 2018

1 reference

Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus

21 January 2018

1 reference

Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes

21 January 2018

1 reference

Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses

21 January 2018

1 reference

Polymorphisms of interferon-λ4 and IL28B - effects on treatment response to interferon/ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

The novel ss469415590 variant predicts virological response to therapy in patients with chronic hepatitis C virus type 1 infection.

21 January 2018

1 reference

Regulation of hepatic innate immunity by hepatitis C virus

21 January 2018

1 reference

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Factors that predict response of patients with hepatitis C virus infection to boceprevir

21 January 2018

1 reference

Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure

21 January 2018

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

Faldaprevir and deleobuvir for HCV genotype 1 infection.

21 January 2018

1 reference

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

21 January 2018

1 reference

Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.

21 January 2018

1 reference

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin

21 January 2018

1 reference

Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis.

21 January 2018

1 reference

Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C.

21 January 2018

1 reference

Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a

21 January 2018

1 reference

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

21 January 2018

1 reference

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

21 January 2018

1 reference

Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C.

21 January 2018

1 reference

A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection.

21 January 2018

1 reference

Classical and emerging roles of vitamin D in hepatitis C virus infection

21 January 2018

1 reference

Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C

21 January 2018

1 reference

Characterization of the human patatin-like phospholipase family

21 January 2018

1 reference

A feed-forward loop amplifies nutritional regulation of PNPLA3

21 January 2018

1 reference

Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities

21 January 2018

1 reference

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

21 January 2018

1 reference

Variant in PNPLA3 is associated with alcoholic liver disease

21 January 2018

1 reference

PNPLA3 (rs738409 C>G) is a common risk variant associated with hepatocellular carcinoma in alcoholic cirrhosis.

21 January 2018

1 reference

The PNPLA3 rs738409 148M/M genotype is a risk factor for liver cancer in alcoholic cirrhosis but shows no or weak association in hepatitis C cirrhosis

21 January 2018

1 reference

Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: Evidence from a meta-analysis of individual participant data

21 January 2018

1 reference

Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis

21 January 2018

1 reference

Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research.

21 January 2018

1 reference

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

21 January 2018

1 reference

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

21 January 2018

1 reference

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

21 January 2018

1 reference

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency.

21 January 2018

1 reference

DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency

21 January 2018

1 reference

The ITPA c.94C>A and g.IVS2+21A>C sequence variants contribute to missplicing of the ITPA gene

21 January 2018

1 reference

Functional study of the P32T ITPA variant associated with drug sensitivity in humans.

21 January 2018

1 reference

Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function

21 January 2018

1 reference

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

21 January 2018

1 reference

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

21 January 2018

1 reference

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

21 January 2018

1 reference

Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort

21 January 2018

1 reference

Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection

21 January 2018

1 reference

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

21 January 2018

1 reference

Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy

21 January 2018

1 reference

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

21 January 2018

1 reference

Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients

21 January 2018

1 reference

Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells

21 January 2018

1 reference

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

21 January 2018

1 reference

EASL clinical practice guidelines: Management of chronic hepatitis B virus infection

21 January 2018

1 reference

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

21 January 2018

1 reference

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

21 January 2018

1 reference

Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.

21 January 2018

1 reference

Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese.

21 January 2018

1 reference

HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B.

21 January 2018

1 reference

IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α.

21 January 2018

1 reference

Genetic variation in IL28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovir.

21 January 2018

1 reference

A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians.

21 January 2018

1 reference

Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean

21 January 2018

1 reference

Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population

21 January 2018

1 reference

Genetic variants in human leukocyte antigen/DP-DQ influence both hepatitis B virus clearance and hepatocellular carcinoma development

21 January 2018

1 reference

Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy

21 January 2018

1 reference

Genetics of HLA disease association

21 January 2018

1 reference

Genome-wide association study of chronic hepatitis B virus infection reveals a novel candidate risk allele on 11q22.3.

21 January 2018

1 reference

Polymorphisms Near IL28B and Serologic Response to Peginterferon in HBeAg-Positive Patients With Chronic Hepatitis B

21 January 2018

1 reference

IFNL3 (IL28B) polymorphism does not predict long-term response to interferon therapy in HBeAg-positive chronic hepatitis B patients.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24654629

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24654629

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1111/APT.12717

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24654629%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24654629%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

24654629

1 reference